What is HC Wainwright's Forecast for BCRX Q3 Earnings?

Key Points

• HC Wainwright raised its Q3 2026 EPS forecast for BioCryst Pharmaceuticals to $0.15 from $0.05 and maintained a Buy rating with a $32 price target.
• BioCryst recently reported quarterly EPS of $0.30, beating the $0.15 consensus estimate, while revenue of $218.25 million exceeded expectations and increased 33.6% year over year.
• Analyst sentiment remains favorable, with eight Buy ratings and four Holds producing a Moderate Buy consensus and an average price target of $20.60, versus the stock’s recent $9.74 price.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - HC Wainwright raised their Q3 2026 earnings per share estimates for BioCryst Pharmaceuticals in a report issued on Thursday, August 6th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn $0.15 per share for the quarter, up from their previous forecast of $0.05. HC Wainwright currently has a "Buy" rating and a $32.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($2.25) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals' FY2026 earnings at ($2.12) EPS, FY2027 earnings at $0.89 EPS, FY2028 earnings at $1.33 EPS, FY2029 earnings at $2.00 EPS and FY2030 earnings at $3.20 EPS.

A number of other research firms have also weighed in on BCRX. Needham & Company LLC reduced their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a report on Wednesday, May 6th. Cantor Fitzgerald increased their price target on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an "overweight" rating in a report on Tuesday, June 30th. Citizens Jmp raised their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a "market outperform" rating in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Finally, Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 8th. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $20.60.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $9.74 on Monday. The stock's 50-day simple moving average is $9.50 and its 200 day simple moving average is $8.84. The stock has a market capitalization of $2.49 billion, a price-to-earnings ratio of -6.49 and a beta of 0.55. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The company had revenue of $218.25 million during the quarter, compared to analysts' expectations of $183.28 million. During the same period in the previous year, the business earned $0.15 earnings per share. The firm's quarterly revenue was up 33.6% compared to the same quarter last year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BCRX. Royal Bank of Canada grew its holdings in BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company's stock worth $476,000 after acquiring an additional 1,458 shares during the last quarter. Cetera Investment Advisers raised its stake in shares of BioCryst Pharmaceuticals by 13.8% during the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company's stock valued at $96,000 after acquiring an additional 1,494 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of BioCryst Pharmaceuticals by 7.4% during the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company's stock valued at $198,000 after acquiring an additional 1,527 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 2,115 shares during the period. Finally, Legato Capital Management LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 10.0% during the fourth quarter. Legato Capital Management LLC now owns 23,949 shares of the biotechnology company's stock worth $187,000 after purchasing an additional 2,172 shares during the period. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source